Xorte logo

News Markets Groups

USA | Europe | Asia | World| Stocks | Commodities

Add a new RSS channel



2023-12-08 21:07:26| Engadget

In a landmark decision, the FDA greenlit two new drugs for the treatment of sickle cell disease in patients 12 and older, one of which Vertexs drug Casgevy is the first approved use of genome editing technology CRISPR in the US. Bluebird Bios Lyfgenia also is a cell-based gene therapy, however, it uses a different gene modification technique to deliver tweaked stem cells to the patient. Both approvals cultivate new pathways for the treatment of sickle cell disease, which is an inherited blood disorder that is characterized by red blood cells that cant properly carry oxygen, which leads to painful vaso-occlusive crises (VOCs) and organ damage. The disease is particularly common among African Americans and, to a lesser extent, among Hispanic Americans. Bone marrow transplants are currently the only cure for sickle cell disease, but they require well-matched donors and often involve complications. #Breaking: The U.S. FDA approves our treatment for #SickleCellDisease. We are excited to make this treatment available to patients. Learn more: https://t.co/9k3p4c7Kyv pic.twitter.com/c5yeqvvv6n Vertex Pharmaceuticals (@VertexPharma) December 8, 2023 While both drug approvals use gene editing techniques, Casgevys CRISPR/Cas9 genome editing works by cutting out or splicing in DNA in select areas. Patients first have blood drawn so that their own stem cells can be isolated and edited with CRISPR. They then undergo a form of chemotherapy to remove some bone marrow cells, so the edited stem cells can be transplanted back in a single infusion. Both drug approvals are based on studies that evaluated the effectiveness and safety of the novel therapies in clinical patients. With Casgevy, study participants reported that they did not experience severe VOCs for at least 12 consecutive months during the 24-month follow-up. Similarly, patients on Lyfgenia did not experience a pain crisis for six to 18 months after the therapy. The FDA's decision comes shortly after UK regulators, as well as the National Health Regulatory Authority in Bahrain both approved Vertexs Casgevy. The approval for a CRISPR-based treatment creates opportunity for further innovation in the gene editing space for treatments ranging from cancers to heart diseases to Alzheimers. Gene therapy holds the promise of delivering more targeted and effective treatments, especially for individuals with rare diseases where the current treatment options are limited, Nicole Verdun, director of the Office of Therapeutic Products at the FDAs Center for Biologics Evaluation and Research said. Casgevy is still currently under review by the European Medicines Agency.This article originally appeared on Engadget at https://www.engadget.com/crispr-based-gene-editing-therapy-approved-by-the-fda-for-the-first-time-200726474.html?src=rss

Category: Marketing and Advertising


Latest from this category

02.03This is what it looks like to reenter Earths atmosphere from a space capsules POV
02.03Two toppled moon landers go dormant for a lunar night they may not survive
02.03Waymo gets approval to deploy its robotaxi service in Los Angeles
01.03Meta is starting to test the Threads API with third-party developers
01.03Apple backtracks on plans to get rid of web apps on iPhones in the EU
01.03Dune 2 kicks butt (literally)
01.03Adobes latest AI experiment generates music from text
01.03Spotify rolls out an audiobook-only subscription
Marketing and Advertising »

All news

03.03I will only cut taxes in responsible way - Hunt
03.03Landmarks: Monees Cut eased steam age rail travel to Chicago, but it came at a price
03.03South Africa: Regulating Data Governance - Swart Attorneys
03.03South Africa: Regulating Data Governance - Swart Attorneys
03.03UK: The CGT 60 Day Rule Explained - Gerald Edelman
03.03UK: The CGT 60 Day Rule Explained - Gerald Edelman
03.03UK: Use Your Inheritance Tax Exemptions - Gerald Edelman
03.03UK: Use Your Inheritance Tax Exemptions - Gerald Edelman
More »
Privacy policy . Copyright . Contact form .